- Author(s): Rachid Zagani, Nadim Hamzaoui, Dominique Lamarque
, Institut national de la santé et de la recherche médicale U567, Centre national de la recherche scientifique (UMR 8104), institut Cochin, université Paris-Descartes, 24, rue du Faubourg-Saint-Jacques, 75014 Paris, France
- Key words: colorectal cancer, prostaglandin
- Page(s) : 137-45
- DOI : 10.1684/hpg.2009.0295
- Published in: 2009
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Classical non-steroidal anti-inflammatory drugs and coxibs, selective inhibitors of cyclo-oxygenase-2 (Cox2), were highly effective in inhibiting tumor growth and preventing CRC in humans and in mice models. Recent reports show that one of the bioactive products of Cox2, prostaglandin E2, activate, after binding to its receptors, multiple intracellular pathways involved in colorectal tumorigenesis. The findings reviewed here reveal important crosstalks between these pathways, which could provide opportunities for the development of new drugs for the treatment and prevention of CRC.